Weight-loss therapy goes pill-to-shot with higher efficacy, convenience

Sales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lilly’s Mounjaro, which has captured ₹450 crore in seven months. Injectables offer higher efficacy and convenience, though experts expect orals to rebound once higher-dose, cheaper versions launch post-2026.

Novo Nordisk shares dip after obesity drug price deal | REUTERS

Shares in Novo Nordisk fell as much as 3% after the Danish drugmaker and US rival Eli Lilly agreed with the US government to lower prices of their blockbuster GLP-1 weight-loss drugs. #News #Reuters #Newsfeed Read the story here: https://reut.rs/4nJ11dF 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow […]

Trump Unveils Deals To Lower Costs Of Some weight-Loss Drugs

WASHINGTON:�US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices of some popular weight-loss drugs, in exchange for relief from threatened tariffs. Both companies “have agreed to offer their most popular GLP-1 weight-loss drug,” Trump said at the White House, “at drastic discounts.””Eli Lilly and Novo […]